Gonadotropin

Global Endocrine Testing Industry (2020 to 2027) - Market Trajectory & Analytics - ResearchAndMarkets.com

Retrieved on: 
Tuesday, September 15, 2020
Health, General Health, Hormones, Branches of biology, Endocrine system, Peptide hormones, Sex hormones, Glycoproteins, Chemical pathology, Human chorionic gonadotropin, Gonadotropin, HCG

The "Endocrine Testing - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Endocrine Testing - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.
  • The 415-page report presents concise insights into how the pandemic has impacted production and the buy side for 2020 and 2021.
  • The U.S. Market is Estimated at $2.3 Billion, While China is Forecast to Grow at 9.9% CAGR
    The Endocrine Testing market in the U.S. is estimated at US$2.3 Billion in the year 2020.
  • In the global Human Chorionic Gonadotropin (hCG) Hormone Testing segment, USA, Canada, Japan, China and Europe will drive the 4.7% CAGR estimated for this segment.

Igyxos and Selexis Enter Service Agreement to Advance Igyxos’ First-In-Class Monoclonal Antibody for the Treatment of Human Infertility

Retrieved on: 
Wednesday, September 2, 2020
Biotechnology, Pharmaceutical, Genetics, Health, Medical specialties, Medicine, Immunology, Health, Biotechnology, Pharmaceutical industry, Immune system, Monoclonal antibody, Gonadotropin, Infertility, Medication, Antibody, Biotechnology, Pharmaceutical, Genetics, Health, Medical specialties, Medicine, Immunology, Health, Biotechnology, Pharmaceutical industry, Immune system, Monoclonal antibody, Gonadotropin, Infertility, Medication, Antibody

Selexis SA and Igyxos announced today that they have entered into a service agreement to develop Igyxos first-in-class monoclonal antibody (mAb) drug candidate for the treatment of human infertility.

Key Points: 
  • Selexis SA and Igyxos announced today that they have entered into a service agreement to develop Igyxos first-in-class monoclonal antibody (mAb) drug candidate for the treatment of human infertility.
  • Under the agreement, Igyxos will utilize Selexis proprietary SUREtechnology Platform to rapidly develop the research cell banks (RCBs) necessary to advance the program to human trials.
  • Therapeutic gonadotropins to treat infertility have been the standard of care since the 1960s.
  • Igyxos mission is to develop new and innovative medical and pharmaceutical technologies in the field of human fertility.

CLARUS THERAPEUTICS ANNOUNCES FINANCING TO SUPPORT THE COMMERCIAL LAUNCH AND AVAILABILITY OF JATENZO® (TESTOSTERONE UNDECANOATE) CAPSULES, CIII FOR THE TREATMENT OF HYPOGONADISM

Retrieved on: 
Monday, March 16, 2020
Hormones, Endocrine system, Branches of biology, Peptide hormones, Sex hormones, Progonadotropins, Glycoproteins, Recombinant proteins, Hypogonadism, Hypogonadotropic hypogonadism, Follicle-stimulating hormone, Gonadotropin

These men usually have low serum testosterone concentrations and gonadotropins (follicle-stimulating hormone [FSH], luteinizing hormone [LH]) above the normal range.

Key Points: 
  • These men usually have low serum testosterone concentrations and gonadotropins (follicle-stimulating hormone [FSH], luteinizing hormone [LH]) above the normal range.
  • Hypogonadotropic hypogonadism (congenital or acquired): gonadotropin or luteinizing hormone-releasing hormone (LHRH) deficiency or pituitary-hypothalamic injury from tumors, trauma, or radiation.
  • Safety and efficacy of JATENZO in males less than 18 years old have not been established.
  • Due to this risk, use JATENZO only for the treatment of men with hypogonadal conditions associated with structural or genetic etiologies.

Ferring Pharmaceuticals to Present New Fertility Data at ASRM 2019 Scientific Congress & Expo

Retrieved on: 
Monday, October 14, 2019
Research, General Health, Pharmaceutical, Genetics, Science, Clinical trials, Biotechnology, Other Science, Health, Medical specialties, Health, Endocrine system, American Society for Reproductive Medicine, Ferring Pharmaceuticals, Reproductive medicine, Gonadotropin

Ferring Pharmaceuticals (US) today announced that it will be presenting five company-sponsored abstracts at the 2019 American Society for Reproductive Medicine (ASRM) Scientific Congress & Expo taking place on October 12-16, 2019, in Philadelphia, Pennsylvania.

Key Points: 
  • Ferring Pharmaceuticals (US) today announced that it will be presenting five company-sponsored abstracts at the 2019 American Society for Reproductive Medicine (ASRM) Scientific Congress & Expo taking place on October 12-16, 2019, in Philadelphia, Pennsylvania.
  • Ferrings first oral presentation will highlight data from MEGASET-HR, which evaluates gonadotropin related differences in follicle endocrine physiology in predicted high responder women undergoing assisted reproductive technology.
  • The second identifies the gap and factors that cause a discrepancy between the potential for and the utilization of fertility care in the U.S.
  • We are excited to present these findings at the 2019 ASRM congress, where leaders in reproductive medicine have been sharing ground-breaking data for 75 years, said Gaurang Daftary, M.D., M.B.A, Senior Medical Director, Ferring Pharmaceuticals.

Teva Announces Launch of a Generic Version of AndroGel® (testosterone gel) 1.62% CIII in the United States

Retrieved on: 
Thursday, April 11, 2019
Health, Pharmaceutical, Consumer, MEN, Hormones, Endocrine system, Branches of biology, Peptide hormones, Sex hormones, Hypogonadotropic hypogonadism, Hypogonadism, Follicle-stimulating hormone, Gonadotropin-releasing hormone, Gonadotropin, Luteinizing hormone, Hypothalamus

Currently, one in eight generic prescriptions dispensed in the U.S. is filled with a Teva generic product.

Key Points: 
  • Currently, one in eight generic prescriptions dispensed in the U.S. is filled with a Teva generic product.
  • These men usually have low serum testosterone concentrations and gonadotropins (follicle-stimulating hormone [FSH], luteinizing hormone [LH]) above the normal range.
  • Hypogonadotropic hypogonadism (congenital or acquired): gonadotropin or luteinizing hormone-releasing hormone (LHRH) deficiency or pituitary-hypothalamic injury from tumors, trauma, or radiation.
  • i AndroGel is a registered trademark of AbbVie, Inc.
    View source version on businesswire.com: https://www.businesswire.com/news/home/20190411005514/en/

Worldwide Human Chorionic Gonadotropin Markets to 2025 - $1.2+ Billion Opportunity Analysis by Technology, Therapeutic Area and End-user - ResearchAndMarkets.com

Retrieved on: 
Wednesday, January 16, 2019
Health, General Health, Endocrine system, Peptide hormones, Sex hormones, Biology, HCG, Gonadotropin, Human chorionic gonadotropin, Draft:TopRatedHCG, AVICINE

The "Human Chorionic Gonadotropin Market by Technology, Therapeutic Area, and End User - Global Opportunity Analysis and Industry Forecast, 2017-2025" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Human Chorionic Gonadotropin Market by Technology, Therapeutic Area, and End User - Global Opportunity Analysis and Industry Forecast, 2017-2025" report has been added to ResearchAndMarkets.com's offering.
  • The global human chorionic gonadotropin (hCG) market generated revenue of $688 million in 2017 and is expected to reach $1,239 million by 2025, registering a CAGR of 7.6% from 2018 to 2025.
  • Rise in incidence of infertility-related problems in both the genders drive the growth of the global hCG market.
  • In addition, upsurge in the adoption of hCG hormone in pain management and weight loss propel the market growth.

Investigation Report on China's Recombinant Human Follitropin Market, 2018-2022 - ResearchAndMarkets.com

Retrieved on: 
Friday, January 11, 2019
Health, Pharmaceutical, Endocrine system, Peptide hormones, Sex hormones, Glycoproteins, Recombinant proteins, Follicle-stimulating hormone, Gonadotropin, Merck Serono, Luteinizing hormone, Urofollitropin, Human chorionic gonadotropin, Gonadotropin preparations

The "Investigation Report on China's Recombinant Human Follitropin Market, 2018-2022" report has been added to ResearchAndMarkets.com's offering

Key Points: 
  • The "Investigation Report on China's Recombinant Human Follitropin Market, 2018-2022" report has been added to ResearchAndMarkets.com's offering
    In China's end markets of ART and sex hormone drugs, macromolecular bioengineered drugs such as Recombinant Human Follitropin, Recombinant Follitropin beta, Recombinant Human Chorionic Gonadotropin, and Recombinant Human Lutropin alfa are taking the place of small-molecule chemicals.
  • According to the researcher, the FSH products in China include Urofollitropin (u-FSH) extracted from urine and Recombinant Human Follitropin (rh-FSH).
  • By the end of 2018, all the Recombinant Human Follitropin products in China were produced by Merck Serono and GeneScience Pharmaceuticals Co., Ltd.
  • 2 Sales of Recombinant Human Follitropin in China, 2013-2017
    3 Analysis of Major Manufacturers of Recombinant Human Follitropin in China, 2013-2017
    4 Prices of Recombinant Human Follitropin in China, 2017-2018
    5 Prospect of China's Recombinant Human Follitropin Market, 2018-2022
    View source version on businesswire.com: https://www.businesswire.com/news/home/20190111005161/en/

China Recombinant Human Lutropin alfa (Luveris) Market, 2018-2022: Market will be Monopolized by Merck Serono by the End of 2018

Retrieved on: 
Monday, January 7, 2019
Peptide hormones, Endocrine system, Sex hormones, Recombinant proteins, Reproduction, Physiology, Glycoproteins, Luteinizing hormone, Merck Serono, Gonadotropin, Gonadotropin preparations

In China's end markets of ART and sex hormone drugs, macromolecular bioengineered drugs such as Recombinant Human Follitropin, Recombinant Follitropin Beta, Recombinant Human Chorionic Gonadotropin, and Human Lutropin alfa are taking the place of small-molecule chemicals.

Key Points: 
  • In China's end markets of ART and sex hormone drugs, macromolecular bioengineered drugs such as Recombinant Human Follitropin, Recombinant Follitropin Beta, Recombinant Human Chorionic Gonadotropin, and Human Lutropin alfa are taking the place of small-molecule chemicals.
  • By the end of 2018, China's Recombinant Human Lutropin alfa market will be monopolized by Merck Serono.
  • It is expected that the pattern of China's Recombinant Human Lutropin alfa market will change in the next few years.
  • 2 Sales of Recombinant Human Lutropin alfa in China, 2013-2017
    2.3 Sales of Recombinant Human Lutropin alfa by Dosage Form in China, 2013-2017
    3 Analysis of Major Recombinant Human Lutropin alfa Manufacturers in China, 2013-2017
    4 Prices of Recombinant Human Lutropin alfa in China, 2017-2018
    5 Prospect of China's Recombinant Human Lutropin Alfa Market, 2018-2022
    Chia Tai Tianqing Pharmaceutical Group Co. Ltd.

Human Chorionic Gonadotropin (hCG) Market to Reach $1,239 Mn, Globally, by 2025 at 7.6% CAGR, Says Allied Market Research

Retrieved on: 
Friday, September 28, 2018
Endocrine system, Peptide hormones, Sex hormones, HCG, Human chorionic gonadotropin, Gonadotropin

According to the report, the global human chorionic gonadotropin (hCG) market garnered $688 million in 2017 and is expected to reach $1,239 million by 2025, growing at a CAGR of 7.6% from 2018 to 2025.

Key Points: 
  • According to the report, the global human chorionic gonadotropin (hCG) market garnered $688 million in 2017 and is expected to reach $1,239 million by 2025, growing at a CAGR of 7.6% from 2018 to 2025.
  • However, warnings and cautions issued by the USFDA regarding the side-effects of hCG therapy would restrain the market growth.
  • Chronic Gonadotropin Market - Global Opportunity Analysis and Industry Forecast, 2017 - 2023
    Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon.
  • Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions."